Blood Lipid Profiles in Metastatic Prostate Cancer: A Window into Tumor Metabolism and Response to Enzalutamide

/in /by

A recent study, published on Nature, in metastatic castration‑resistant prostate cancer (mCRPC) shows that a simple blood test can reveal important information about how the tumor is reprogramming its metabolism and how it responds to enzalutamide, a common androgen‑receptor‑targeting drug. Researchers analyzed the entire circulating “lipidome” (the full panel of fats and related molecules in […]

Read more

Organoids from Routine TUR‑P Samples: A Personalized Platform for Prostate Cancer Therapy Testing

/in /by

A new preclinical study shows how a simple tissue sample can be turned into a powerful tool for understanding and treating advanced prostate cancer. Researchers have developed a method to grow patient‑derived organoids from prostate tissue fragments removed during routine transurethral resection of the prostate, or TUR‑P, a common procedure often done for urinary symptoms. […]

Read more

Estrogen‑Based Androgen Suppression Plus ARSI in Prostate Cancer: A Phase 2 Quality‑of‑Life Trial

/in , , /by

A new phase 2 EQUIP trial is comparing two different ways of delivering androgen‑suppressive hormone therapy in men with newly diagnosed or recurrent metastatic hormone‑sensitive prostate cancer, focusing on whether transdermal estrogen patches can improve quality of life compared with standard luteinizing hormone‑releasing hormone (LHRH) analogues. The study is designed around two randomized cohorts, each […]

Read more

GLR2037: A First‑in‑Human AR‑Targeted PROTAC Enters Phase 1 Trials in Advanced Prostate Cancer

/in , , /by

A new investigational agent code‑named GLR2037 has entered early clinical development as a first‑in‑human phase 1 study in patients with advanced prostate cancer, representing a significant step in the evolution of androgen receptor–directed therapies. GLR2037 is an androgen receptor (AR)–targeting proteolysis‑targeting chimera (PROTAC), designed not merely to inhibit the AR but to promote its ubiquitin‑proteasome–mediated […]

Read more

Durable PSA Control After Testosterone Recovery in High‑Risk Biochemical Recurrent Prostate Cancer

/in /by

A recent post hoc analysis of the phase 3 EMBARK trial in high‑risk biochemical recurrent prostate cancer has generated considerable interest because it suggests that durable, long‑term PSA control can occur even after testosterone has fully recovered to eugonadal levels, challenging the conventional assumption that hormonal suppression must be continuous to maintain remission. The analysis […]

Read more

Amino Acid Mix Supercharges Lipid Nanoparticle Delivery for mRNA and CRISPR Therapies

/in , /by

Scientists have discovered that a simple mix of three amino acids can greatly improve how well lipid‑nanoparticle (LNP)–based therapies work in the body. These LNPs are tiny fat‑like packages used to carry mRNA or CRISPR components into cells, and they are already at the heart of new vaccines and gene‑editing treatments. The new finding suggests […]

Read more

The ENHANCE Phase 3 Trial Tries to Cuts Hormone Therapy Side Effects

/in , , /by

Hormone therapy has been a cornerstone for treating advanced prostate cancer, starving tumors of the male hormones they crave to grow. But it often brings harsh side effects like crushing fatigue, hot flashes, high blood pressure, and loss of muscle mass that make daily life a struggle for many men. Now, a major new UK […]

Read more

HITMAN-PC Phase 1 Results: Hydroxychloroquine + SUBA-Itraconazole Stabilizes Biochemical Prostate Cancer Relapse

/in , , /by

The HITMAN-PC trial represents a targeted metabolic approach to managing biochemical relapse in prostate cancer, combining hydroxychloroquine (HCQ) and SUBA-itraconazole (SI) to disrupt lysosomal function and cholesterol trafficking in hormone-sensitive disease. In this phase 1 dose-escalation study, 11 men (median age 73, baseline PSA 4.4 ng/mL, PSA doubling time 5.3 months) received fixed SI at […]

Read more